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Abstract
Introduction Positron emission tomography (PET) is suggested
for early monitoring of treatment response, assuming that
effective anticancer treatment induces metabolic changes that
precede morphology alterations and changes in growth. The aim
of this study was to introduce multicellular tumour spheroids
(MTS) to study the effect of anticancer drugs and suggest an
appropriate PET tracer for further studies.
Methods MTS of the breast cancer cell line MCF7 were
exposed to doxorubicin, paclitaxel, docetaxel, tamoxifen or
imatinib for 7 days for growth pattern studies and for 3 or 5 days
for PET tracer studies. The effect on growth was computed
using the semi-automated size determination method (SASDM).
The effect on the uptake of PET tracers [18F]3'-deoxy-3'-
fluorothymidine (FLT), [1-11C]acetate (ACE), [11C]choline
(CHO), [11C]methionine (MET), and 2-[18F]fluoro-2-
deoxyglucose (FDG) was calculated in form of uptake/viable
volume of the MTS at the end of the drug exposures, and finally
the uptake was related to effects on growth rate.
Results The drugs paclitaxel, docetaxel and doxorubicin gave
severe growth inhibition, which correlated well with inhibition of
the FLT uptake. FLT had, compared with ACE, CHO, MET and
FDG, higher sensitivity in monitoring the therapy effects.
Conclusion SASDM provides an effective, user-friendly, time-
saving and accurate method to record the growth pattern of the
MTS, and also to calculate the effect of the drug on PET tracer
uptake. This study demonstrate the use of MTS and SASDM in
combination with PET tracers as a promising approach to probe
and select PET tracer for treatment monitoring of anticancer
drugs and that can hopefully be applied for optimisation in
breast cancer treatment.
Introduction
Positron emission tomography (PET) has demonstrated use-
fulness in monitoring therapeutic response in a wide range of
cancers, including breast cancer [1,2]. This is because effec-
tive therapy leads to rapid physiological modification in
tumours; with the right choice of PET tracer, this modification
can easily be revealed and the therapeutic response can be
clarified [3]. Physicians can thus quickly modify less effective
therapy, thereby improving patient outcomes and reducing the
cost of ineffective treatment.
To date, 2-[18F]fluoro-2-deoxyglucose (FDG) has been the
most common PET tracer; however future applications of PET
will likely involve other tracers to improve characterisation of
tumour biology and more effectively measure response to ther-
apy [4,5]. This potential refinement in tumour characterisation
will help to predict clinical behaviour and tailor therapy of
tumour biology, thereby individualising treatment.
In preclinical investigations, the multicellular tumour spheroid
(MTS) system has provided an appropriate in vitro system to
ACE = [1-11C]acetate; CHO = [11C]choline; FDG = 2-[18F]fluoro-2-deoxyglucose; FLT = [18F]3'-deoxy-3'-fluorthymifine; MET = [11C]methionine; 
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evaluate and predict tumour response to chemotherapy
agents [6-8]. It has been clearly shown that MTS are function-
ally and physiologically superior to monolayer cultures [9-14].
Another important advantage of MTS is the possibility for long-
term follow up. We have previously shown that MTS in combi-
nation with the semi-automated size determination method
(SASDM) [15] is suitable for preclinical studies of PET tracer
uptake, with simplified handling during incubation, washing
and measurements [16].
This study aimed to illustrate the practicality of the method and
to indicate the potential to correlate drug effects on PET tracer
uptake (short-term effect) with their effects on spheroid
growth (long-term effect) by including five different anticancer
drugs and five different PET tracers. This introduces the pos-
sibility of using the MTS model in combination with SASDM as
an applicable preclinical method to screen a range of PET
tracers for breast cancer treatment monitoring.
Materials and methods
Cell culture
Cells of the MCF-7, oestrogen receptor positive human breast
cancer line (European Collection of Cell Cultures, Salisbury,
UK) were grown in MEM/EBSS supplemented with 10% FCS,
1 mM sodium pyruvate, 2 mM L-glutamine, 1% non-essential
amino acids and 5% penicillin (Tamro, Vantaa, Finland). The
medium was changed twice weekly and cells were maintained
in exponential growth phase.
Multicellular tumour spheroids
The tumour cells were trypsinised from the stem monolayer
culture. Cell suspensions were then seeded in 24-well, 1%
agarose-coated culture plates, with approximately 50000 cells
per well. MTS were grown in DMEM (high glucose) supple-
mented with 10% FCS, 1 mM sodium pyruvate, 2 mM L-
glutamine, 1% non-essential amino acid, 5% penicillin, 0.01
mg/ml insulin and 1 nM β-estradiol (Tamro), and were kept at
37°C with 5% CO2. After 6 days, stable spheroids had formed
that were approximately 1.2 mm in diameter.
Anticancer drug treatment
The five anticancer agents: paclitaxel, docetaxel, doxorubicin,
tamoxifen and imatinib were obtained from Novartis (Basel,
Switzerland) and diluted in the growing culture medium to a
concentration of 1 μM or 10 μM. The recommended dose for
patients is in the range of 1–10 μM, if an equal distribution of
the drug in body is assumed. Treatment was initiated at day 6
of MTS growth with changing the culture medium to the drug-
containing medium. After 1 h the medium with drug was
renewed to ensure adequate mixing.
In each experimental set-up, four MTS in one 24-well plate
were referred to as one group. The groups included control
(without treatment agent) and five different treatment drugs
with the same concentration.
The response to each anticancer treatment was evaluated by
measurement of the tracer uptake and viable volume of the
MTS after 3 and 5 days of treatment. Additionally, each sphe-
roid was photographed before and during drug treatment
using a Nikon Colorpix 4500 (Nikon, Tokyo, Japan) camera
mounted on an inverted Zeiss microscope (Carl Zeiss Micro-
Imaging, Inc. Thornwood, New York, USA). The digital images
were stored for evaluation of size.
Semi-automated size determination method (SASDM)
Digital images of MTS were evaluated with respect to area of
total spheroid, rim of viable cells and central necrosis using
SASDM software, as previously described [15]. Knowing the
area of total spheroid and area of central necrosis, the respec-
tive volumes were calculated assuming the third dimension to
be described by the geometric mean of the diameters of an
ellipsoid with the same area as determined. Finally the volume
of viable cells was calculated as the difference between the
total volume and the volume of the necrosis.
PET tracers
To monitor the effect of each anticancer treatment five estab-
lished PET tracers were used: [1-11C]acetate, [11C]choline,
[11C]methionine, [18F]3'-deoxy-3'-fluorothymidine and 2-
[18F]fluoro-2-deoxyglucose. All were synthesised immediately
prior to use at the PET centre of Uppsala Imanet according to
standard procedures.
PET tracer uptake
The MTS were incubated for 50 min (for 18F-labelled tracers)
and 30 min (for 11C-labelled tracers) at 37°C with 0.5 ml
medium per well containing 3 MBq tracer, and then washed 3
× 5 min (for 18F-labelled tracers) and 3 × 3 min (for 11C-
labelled tracers) with medium (1 ml/well). Finally, MTS with 20
μl washing medium were transferred to 5 ml tubes and tracer
uptake was measured in a calibrated well γ-counter. A 20 μl
sample of the incubation medium was measured as reference,
and 20 μl from the last wash medium was measured as back-
ground control.
For each spheroid in each treatment group the total tracer
uptake (activity concentration (Bq/ml)) and the tracer uptake
per viable volume MTS (activity concentration (Bq/ml)/viable
volume (mm3)) were determined, and the averages over the
treatment groups were normalised to the control group. Each
experimental set-up was repeated three times.
Dose effect study
Based on the PET screening and dose-dependence result, the
dose effect of docetaxel and doxorubicin were investigated,
using [18F]3'-deoxy-3'-fluorothymidine (FLT) as tracer.
The MTS were treated with different doses of docetaxel (1, 3,
5, 10 or 20 μM) and doxorubicin (0.1, 1, 3, 5, or 10 μM) andAvailable online http://breast-cancer-research.com/content/9/4/R45
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then the FLT uptake in the MTS were measured after 3 days of
treatment.
Growth pattern study
The effect of each chemotherapy agent on growth pattern was
investigated. The size determinations included assessment of
total MTS volume, including central necrosis, and viable cell
volume in which case only the rim of viable cells were included.
The relative volumes were presented in percent of starting vol-
ume and presented in relation to days after start of treatment.
To determine effect on growth, the following calculations and
illustrations were made. The growth rate for each dose group
was calculated as:
τ = 0.693/Td
where the growth pattern was fitted to the equation:
V = V0*Exp(τ*t).
This equation assumes exponential growth, starting with the
initial volume of V0, and with a doubling time of Td.
Effect on growth rate was expressed as:
100*(τ0-τD)/τ0
where τ0 denotes growth rate without drug and τD denotes
growth rate with drug. This indicated that lack of drug effect is
given as 0%, total growth cessation as 100% and regression
as a value larger than 100%.
The reduction in tracer uptake in MTS was defined as:
100*(U0-UD)/U0
where U0 represents activity concentration (Bq/ml)/viable vol-
ume (mm3) of MTS without treatment and UD represents activ-
ity concentration (Bq/ml)/viable volume (mm3) of MTS with
treatment.
Finally, the effect of each drug in form of growth retardation
and reduction in PET tracer uptake was correlated.
Ki67 staining
Proliferation of tumour cells within spheroids was assessed by
Ki67 staining. At 3 days after treatment spheroids were
washed in medium, fixed in 4% paraformaldehyde and placed
in paraffin blocks. Serial 4-μm sections of the paraffin blocks
were cut using a cryotome and mounted on poly-L-lysine-
coated slides that were fixed in hydrogen peroxide and 90%
methanol. Ki67 staining was performed using a monoclonal
mouse antibody directed against Ki67 and MOM kit (Vector
Labs, Burlingame, CA, USA). Images were captured digitally
using a Nikon Colorpix 4500 camera mounted on an inverted
Zeiss microscope.
Results
Drug-induced growth disturbances
All drugs, except imatinib, showed a clear effect in the form of
growth rate reduction or even regression of size of MTS. In
MTS treated with 10 μM imatinib, a slight growth enhance-
ment was observed. Growth inhibition observed in MTS
treated with doxorubicin and tamoxifen showed more apparent
dose dependence compared to the taxanes (Table 1).
Uptake of the PET tracers
The relative uptake (activity in viable part of the MTS/activity in
incubation medium) of all PET tracers was in the range of 1–
1.5. However, this relative moderate uptake in relation to
medium does not translate into a moderate contrast in vivo, as
there the background is washed out significantly with time.
The uptake of the PET tracers after 3 days of drug exposure is
shown in Table 2.
Paclitaxel
In MTS treated with paclitaxel, an inhibitor of microtubule
remodelling, FLT uptake decreased by about 70%. FDG
uptake decreased slightly but not as much as FLT, and altera-
tion in [11C]choline (CHO), [11C]methionine (MET) and [1-
11C]acetate (ACE) uptake was insignificant.
Docetaxel
In MTS treated with docetaxel, also an inhibitor of microtubule
remodelling, FLT uptake decreased by about 70%. FDG
uptake decreased slightly but not as much as FLT, and
alteration in CHO, MET and ACE uptake was insignificant.
PET tracer uptake showed a similar pattern as in MTS treated
with paclitaxel.
Table 1
The effect of chemotherapy agents on growth pattern
Treatment Dose (μM) % Growth inhibition
Paclitaxel 1 141
10 200
Docetaxel 1 126
10 144
Doxorubicin 1 188
10 360
Tamoxifen 1 36
10 127
Imatinib 1 0
10 -12Breast Cancer Research    Vol 9 No 4    Monazzam et al.
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Doxorubicin
In MTS treated with doxorubicin, an anthracycline antibiotic,
FLT uptake decreased considerably by about 90% but uptake
of FDG, CHO, MET and ACE decreased less.
Tamoxifen
In MTS treated with tamoxifen, an anti-oestrogen, significant
tracer uptake alteration was observed only in the 10 μM dose.
FLT and FDG uptake decreased by about 20%, CHO and
MET uptake was barely affected, whereas ACE uptake
increased by about 40%.
Imatinib
In MTS treated with imatinib, a protein-tyrosine kinase inhibitor,
tracer uptake alteration was observed only with the 10 μM
dose. FLT uptake was hardly affected, FDG and CHO uptake
decreased by about 20% and MET and ACE uptake was not
significantly changed.
Correlation between tracer uptake and growth
The drug-induced changes in uptake of PET tracers as a func-
tion of the drug-induced growth disturbances are plotted in
Figure 1. FLT seemed to be the most appropriate PET tracer
for treatment follow-up of MTS. FLT responded with reduction
in uptake shortly after treatment in correlation with the growth
inhibition. A reduced growth rate of more than 100% was
associated with more than 70% reduction in FLT uptake for
paclitaxel, docetaxel and doxorubicin. However, on treatment
with tamoxifen, a growth inhibition was noted in spite of only
20% reduction of FLT uptake.
For FDG, the high reduction of growth rate was associated
with about 25% reduction in tracer uptake in spheroids
treated with taxanes, doxorubicin and 10 μM tamoxifen. The
uptake of the tracers CHO, MET and ACE showed small
changes or in some cases even increases in spite of signifi-
cant growth inhibition effects by the drugs.
Dose effect of docetaxel and doxorubicin
In a separate study on the dose effects, FLT uptake decreased
gradually with increased doses of doxorubicin (Figure 2). This
was in contrast to the results after docetaxel exposure.
The experiment suggests that the maximum effect of docetaxel
occurs below 1 μM, which is consistent with the potential that
docetaxel saturates its target. The slight increase with dose
observed could relate to other phenomena exerted by
docetaxel, e.g. related to changes in cellular contact.
The results were consistent with the effects on growth where
a minor dose relation was observed with docetaxel whereas a
major dose relation was observed with doxorubicin (Table 1).
However, the effect of docetaxel in FLT uptake in these exper-
iments was more moderate than the effect observed in the
experiments performed earlier (PET tracer uptake experi-
ments). The explanation is likely related to the different condi-
tions of the experiments, e.g. different batches of the MCF-7
cell line and different batches of medium.
Immunohistochemistry
Ki67 staining of spheroid sections depicted a decrease in pro-
liferating cells in MTS treated with taxanes and doxorubicin
(Figure 3).
Discussion
Effective chemotherapy is expected to induce various meta-
bolic changes in tumours that are followed by alterations in
morphology and growth inhibition, unregulated cell death or
apoptosis. It can be assumed that the physiological changes
occur before changes in the tumour size can be observed. This
Table 2
The effect of chemotherapy agents on tracer uptake after 3-day treatment
Treatment Dose (μM) % PET Tracer uptake reduction
FLT FDG CHO MET ACE
Paclitaxel 1 68 ± 7 21 ± 8 -13 ± 9 6 ± 7 -10 ± 7
10 69 ± 7 17 ± 7 -6 ± 9 7 ± 7 -10 ± 8
Docetaxel 1 66 ± 6 27 ± 7 -3 ± 7 13 ± 6 1 ± 5
10 66 ± 6 27 ± 6 -2 ± 7 1 ± 6 -7 ± 5
Doxorubicin 1 76 ± 5 18 ± 5 5 ± 6 -8 ± 5 14 ± 5
10 95 ± 6 71 ± 6 27 ± 8 38 ± 9 48 ± 7
Tamoxifen 1 11± 8 2 ± 9 -2 ± 9 0 ± 7 -7 ± 7
10 28 ± 7 22 ± 8 -2 ± 9 -7 ± 7 -45 ± 7
Imatinib 1 7 ± 7 3 ± 9 4 ± 9 -6 ± 7 2 ± 7Available online http://breast-cancer-research.com/content/9/4/R45
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is the principle behind the concept that an efficient chemother-
apy can be detected with PET at earlier stages than with other
types of imaging modalities. However, the question remains
which metabolic modifications will occur after a specific chem-
otherapy, and which PET tracer is most sensitive in detecting
those modifications. Of equal importance is ascertaining when
a treatment induces metabolic changes that are recordable
with PET that do not translate into an anti-tumoural action such
as inhibition of growth.
Although there is a relatively good understanding of the mech-
anisms by which certain anticancer drugs exert their effect,
and it is relatively well known by which mechanisms certain
PET tracers accumulate in tumour cells, it is usually less obvi-
Figure 1
Correlation between growth inhibition and tracer-uptake reduction after 3 days of treatment (1 and 10 μM) Correlation between growth inhibition and tracer-uptake reduction after 3 days of treatment (1 and 10 μM).
Figure 2
The dose effect of treatment with docetaxel and doxorubicin recorded with FLT The dose effect of treatment with docetaxel and doxorubicin recorded with FLT.Breast Cancer Research    Vol 9 No 4    Monazzam et al.
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ous how these mechanisms are interrelated. The correlation is
especially difficult to predict with PET tracers that reflect
rather general physiological phenomena, e.g. there is no obvi-
ous connection between microtubule inhibition and expres-
sion of glucose transporters. Hence, without an understanding
of these links, we must revert to empirical evaluations of corre-
lations. This increases the complexity of the situation, as cor-
relations observed in a certain assay with its own experimental
conditions might not be relevant for other conditions. For
example, observations made with a certain time of drug expo-
sure might not be reproduced with another drug schedule. In
this sense, we believe that the proposed assay is an important
methodological contribution because it allows a work-efficient
way of exploring different experimental schemes, and the
spheroid model allows variable scheduling to be simulated.
The aim of the present study was to explore our assumptions
and to complement our previous studies on use of MTS and
monitoring of PET tracer uptake by illustrating its ease and
potential using five different drugs and five different PET trac-
ers available at multiple PET centres, all of which have shown
usefulness in the diagnosis of different types of cancer. Of
special importance has been the use of the semi-automated
size determination method (SASDM), as it allows an accurate
and precise assessment of the volume of viable cells in the
spheroids. This in turn gives us an opportunity to define tracer
uptake in relation to viable volume and not only the total vol-
ume, which is especially important in long-term studies and
drug effect studies where the proportion between viable vol-
ume and necrosis can be expected to change. Furthermore, it
allows a better estimate of growth rate and effect on growth
rate by treatment.
The use of ACE in PET has been suggested in urologic malig-
nancies, hepatocellular carcinoma (HCC) and cardiac dis-
ease. The mechanism of tumour retention of this tracer differs
from that of myocardium, in which ACE is incorporated into the
citric acid cycle and rapidly metabolised. The dominant proc-
Figure 3
Ki67 staining of spheroid sections illustrating proliferating cells (black colour) after 3-day exposure to 1 μM non-drug medium (a), paclitaxel (b),  docetaxel (c), doxorubicin (d), tamoxifen (e) and imatinib (f) Ki67 staining of spheroid sections illustrating proliferating cells (black colour) after 3-day exposure to 1 μM non-drug medium (a), paclitaxel (b), 
docetaxel (c), doxorubicin (d), tamoxifen (e) and imatinib (f).Available online http://breast-cancer-research.com/content/9/4/R45
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ess of ACE incorporation in tumours is thought to be
participation in lipid synthesis [17]. In this study, an increase
of ACE uptake, from non-significant with docetaxel to 40%
with tamoxifen, to a decrease by 30% with doxorubicin, was
observed. Hence, compared with other tracers, ACE seemed
to have less utility for the monitoring of breast cancer
treatment.
In the human body, choline is needed for the synthesis of
phospholipids in cell membranes, methyl metabolism, trans-
membrane signalling, and lipid-cholesterol transport and
metabolism. The uptake is transport mediated and intracellular
choline is rapidly metabolised to phosphorylcholine (PC); it
can also undergo acetylation to form acetylcholine or oxidation
to form betaine (mainly in liver and kidney). The phosphoryla-
tion is catalysed by the enzyme choline kinase. After phospho-
rylation, the polar PC molecule is trapped within the cell.
Various studies have revealed an increased choline uptake as
well as an up-regulated activity of choline kinase and elevated
levels of PC in cancer cells [18]. Although a primary use is in
prostate cancer, it has also been suggested that CHO could
be a potential PET tracer for imaging of breast cancer [19]. In
this study, a 10 to 20% decrease of CHO uptake in MTS
treated with doxorubicin and imatinib was observed. However,
for doxorubicin treatment the decrease in uptake was much
less than growth inhibition and for imatinib, the decrease was
a false indication of treatment efficiency.
MET has been suggested as a tumour imaging agent [20-22].
The uptake of MET reflects increased amino acid transport
and, in part, protein synthesis; it also is related to cellular pro-
liferation activity. In MTS treated with paclitaxel, docetaxel and
doxorubicin, MET uptake decreased slightly but to a lesser
extent than the growth inhibition.
FLT has become one of the promising PET agents that reflect
nucleoside transport into the cell and has been proposed as a
marker for cellular proliferation [23-26]. FLT is phosphorylated
by thymidine kinase-1 and then trapped intracellularly by enter-
ing the salvage pathway of DNA synthesis without incorpora-
tion into the DNA molecule. The FLT uptake was considerably
decreased during 3 days of treatment with paclitaxel,
docetaxel, doxorubicin and high dose of tamoxifen where also
a growth inhibition was observed. The modest FLT uptake
increase observed in imatinib treatment was correlated to the
moderate growth enhancement. Ki67 staining illustrated and
confirmed the anti-proliferative effect of the drugs monitored
with FLT.
FDG is the most commonly used PET tracer in cancer diagno-
sis and has shown utility for treatment monitoring for selected
agents. FDG uptake reflects glucose transporters expression
and hexokinase in the cells, dual mechanisms that lead to fluor-
odeoxy-glucose-phosphate accumulating without further
metabolism. It is the most commonly used PET tracer for diag-
nosis and treatment follow-up of breast cancer. FDG uptake
reduced as a result of treatment with taxanes, doxorubicin [16]
and the higher dose of tamoxifen. FDG uptake reduction cor-
related with growth inhibition, but not as clearly as FLT.
Our results showed high sensitivity of FLT, compared with
FDG and other tracers, for monitoring the effects of the drugs
in MTS. This is an example where PET tracers other than FDG
seem necessary to improve the ability to measure and predict
response and hopefully help to tailor therapy to individual
patients. This study only used one cell line, MCF-7, and aimed
primarily to show the methodology. To allow more general con-
clusions with respect to treatment monitoring of breast
cancer, it would be necessary to explore further breast cancer
cell lines, evaluate more concentrations of the drugs, investi-
gate the time courses of drug effects by using pulse treatment,
and probe more carefully the uptake pattern of the PET
tracers.
There are also many additional factors that should be consid-
ered, e.g. concentrations of glucose, methionine and choline in
the cell culture medium that are 5–10-fold higher compared to
blood.
Conclusion
This study shows the possibility of using MTS as a practical
preclinical model to screen a range of PET tracers for breast
cancer treatment monitoring. This, in combination with
SASDM, improves the precision and allows accurate studies
of the correlation between changes in PET tracer uptake and
effects on growth of the MTS. We demonstrate the feasibility
of in vitro quickly assessing a metabolic response profile of
existing and newly developed anticancer drugs.
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